More about

Cholestatic Pruritus

News
July 25, 2024
1 min read
Save

FDA expands Livmarli approval for pruritus in PFIC to infants as young as 12 months

FDA expands Livmarli approval for pruritus in PFIC to infants as young as 12 months

The FDA has updated the label indication for Livmarli for the treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis, expanding the patient population to include infants aged 12 months and older.

News
March 14, 2024
1 min read
Save

FDA approves Livmarli for pruritus in progressive familial intrahepatic cholestasis

FDA approves Livmarli for pruritus in progressive familial intrahepatic cholestasis

The FDA has approved Mirum Pharmaceuticals’ Livmarli oral solution for treatment of cholestatic pruritus in patients aged 5 years and older with progressive familial intrahepatic cholestasis, according to a company release.